|
|
Article: FDA Advisory Committee Recommends Approval for Glaxo Wellcome Drug Lotronex(TM) (alosetron hydrochloride) for the Treatment of Irritable Bowel Syndrome in Women.
- Article from:
- PR Newswire
- Article date:
- November 16, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WASHINGTON, Nov. 16 /PRNewswire/ -- The investigational drug Lotronex(TM) (alosetron hydrochloride), the first of a new generation of agents being studied specifically for the treatment of multiple symptoms of irritable bowel syndrome (IBS), was recommended for approval today by a unanimous vote of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee. The committee recommended Lotronex for use in women with IBS for whom diarrhea is a predominant symptom. While the favorable recommendation of the Advisory Committee is not binding, the FDA generally follows the advice of its expert panel members.
The advisory committee's action followed ...